BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Type 2 diabetes clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for type 2 diabetes: 370 (175 sponsors; 109 newly posted in the last 180 days, 7 stopped in the last 180 days; 37 new-entrant sponsors). Momentum score 31.1, rank 5 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 54, Phase 2 68, Phase 3 112, Phase 4 21, N/A 114.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Eli Lilly and Company LLY | 32 | P3 17, P1 5, P2 7, P4 3 | 9 | 5 |
| Novo Nordisk A/S NVO | 35 | NA 10, P3 12, P1 7, P2 4, P4 2 | 17 | 3 |
| AstraZeneca AZN | 18 | P3 11, P1 3, NA 3, P2 1 | 13 | 5 |
| Amgen AMGN | 9 | P1 2, P3 6, P2 1 | 3 | 3 |
| Gan & Lee Pharmaceuticals. | 9 | P2 2, P3 5, P1 2 | 1 | 1 |
| Hoffmann-La Roche | 9 | P3 5, P2 2, P1 1, NA 1 | 4 | 0 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 8 | P3 5, P2 1, P4 2 | 0 | 1 |
| EMS | 4 | P3 4 | 0 | 0 |
| Viking Therapeutics, Inc. VKTX | 4 | P3 4 | 2 | 0 |
| Pfizer PFE | 3 | P3 3 | 1 | 0 |
| Jiangsu HengRui Medicine Co., Ltd. | 5 | P2 2, P3 2, P1 1 | 2 | 2 |
| Boehringer Ingelheim | 3 | P3 2, NA 1 | 1 | 1 |
| The United Bio-Technology (Hengqin) Co., Ltd. new entrant | 3 | P3 2, P1 1 | 3 | 0 |
| Beijing Dongfang Biotech Co., Ltd. | 2 | P3 2 | 0 | 0 |
| BrightGene Bio-Medical Technology Co., Ltd. | 2 | P3 2 | 1 | 1 |
| Guangdong Raynovent Biotech Co., Ltd | 2 | P3 2 | 0 | 2 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2 | P3 2 | 0 | 2 |
| Daewoong Pharmaceutical Co. LTD. | 6 | P1 1, NA 4, P3 1 | 1 | 0 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | 6 | P1 3, P3 1, P2 2 | 3 | 5 |
| Boryung Pharmaceutical Co., Ltd | 4 | NA 2, P4 1, P3 1 | 0 | 2 |
| Dong-A ST Co., Ltd. | 3 | P2 1, P4 1, P3 1 | 0 | 1 |
| Addpharma Inc. new entrant | 2 | P1 1, P3 1 | 2 | 0 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | 2 | P3 1, P2 1 | 1 | 0 |
| Hanmi Pharmaceutical Company Limited HAFC | 2 | P3 1, P2 1 | 0 | 0 |
| Vertex Pharmaceuticals Incorporated VERX | 2 | P3 1, P2 1 | 0 | 1 |
New-entrant sponsors: The United Bio-Technology (Hengqin) Co., Ltd., Addpharma Inc..
Recently stopped trials
- NCT05631431 CuraLife - terminated: The study was stopped due to suspicion of a safety issue that was later found to be negligible Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus
- NCT00814372 Gilead Sciences - terminated: MBX-102 did not meet the target efficacy profile of HbA1c change. Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
- NCT07030868 Eli Lilly and Company - terminated: Study terminated for strategic business reasons A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
- NCT04628481 Dompé Farmaceutici S.p.A - terminated: The study was stopped due to futility as per protocol A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
- NCT03686657 ARKAY Therapeutics - withdrawn: Clinical stage asset and the sponsorship have been acquired by Myopharm Limited. Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
- NCT07357740 Novo Nordisk A/S - withdrawn: The study is withdrawn due to strategic reasons. A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
- NCT07014735 Richmond Pharmacology Limited - terminated: The study is being terminated early on the grounds of futility, as continuation of the study is no longer considered scientifically or opera Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Boryung Pharmaceutical Co., Ltd | NCT06220773 A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | Essential Hypertension; Type 2 Diabetes Mellitus | recruiting | 276 |
| 2026-12 est. | P3 | Celltrion | NCT07093476 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | T2DM; Diabete Type 2; DM | recruiting | 171 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07487103 Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Type 2 Diabetes | not yet recruiting | 478 |
| 2026-12-01 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07139535 A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | T2DM | not yet recruiting | 350 |
| 2026-12-01 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT07139548 A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes | T2DM | not yet recruiting | 600 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | active not recruiting | 1105 |
| 2027-02 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT07060456 Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | Type 2 Diabetes | recruiting | 300 |
| 2027-02 est. | P2 | Antag Therapeutics | NCT07724340 A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweigh | Adults With Overweight/Obesity and Type 2 Diabetes | active not recruiting | 150 |
| 2027-02-11 est. | P2 | Gan & Lee Pharmaceuticals. | NCT07387003 Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | Type 2 Diabetes (T2DM) | not yet recruiting | 345 |
| 2027-02-14 est. | P3 | Hudson Biotech | NCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | recruiting | 2539 |
| 2027-02-16 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07082114 A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | recruiting | 800 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-04 est. | P3 | CMG Pharmaceutical Co. Ltd | NCT06772168 Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia | Dyslipidemia; Type 2 Diabetes | recruiting | 240 |
| 2026-11-04 | P3 | THPharm Corp. | NCT06647745 A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP | Type 2 Diabetes; Hypertension | active not recruiting | 222 |
| 2026-10-30 est. | P3 | CSPC Ouyi Pharmaceutical Co., Ltd. | NCT07026968 A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes | Type 2 Diabetes | active not recruiting | 815 |
| 2026-10-26 | P3 | Eli Lilly and Company LLY | NCT06297603 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Ba | Type 2 Diabetes | active not recruiting | 341 |
| 2026-10-18 est. | P2/P3 | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | NCT07033585 Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers | Type 2 Diabetes | active not recruiting | 600 |
| 2026-10-10 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07193459 Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | recruiting | 360 |
| 2026-10 est. | P2 | Housey Healthcare ULC | NCT07546929 HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes | Type 2 Diabetes | recruiting | 300 |
| 2026-09-18 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss | completed | 58 |
| 2026-09-18 | P3 | Gan & Lee Pharmaceuticals. | NCT06778967 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | completed | 1133 |
| 2026-09-01 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06606093 Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients | Type 2 Diabetic Nephropathy | not yet recruiting | 348 |
| 2026-08-25 | P3 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06716216 A Study of BGM0504 in Participants With Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | completed | 553 |
| 2026-08-13 | P2 | Zealand Pharma ZEAL.CO | NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Overweight; Type 2 Diabetes; Obesity | completed | 221 |
| 2026-08-13 | P3 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06716203 A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Type 2 Diabetes Mellitus (T2DM) | completed | 227 |
| 2026-08-10 | P2 | Ascletis Pharma (China) Co., Limited | NCT07321678 A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | T2DM (Type 2 Diabetes Mellitus) | completed | 100 |
| 2026-07-30 | P3 | Gan & Lee Pharmaceuticals. | NCT06777238 A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Di | Type 2 Diabetes Mellitus (T2DM) | completed | 274 |
| 2026-07-18 | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06649344 A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 | Type 2 Diabetes | completed | 884 |
| 2026-07-06 | P2 | Eli Lilly and Company LLY | NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D | completed | 134 |
| 2026-07 est. | P3 | EMS | NCT05028140 Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus | Type II Diabetes | recruiting | 480 |
| 2026-07 est. | P3 | EMS | NCT04670666 Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus | Type 2 Diabetes Mellitus | recruiting | 270 |
| 2026-06-29 | P3 | Novo Nordisk A/S NVO | NCT07271251 A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People Wi | Type 2 Diabetes | completed | 267 |
| 2026-06-28 est. | P2 | Gan & Lee Pharmaceuticals. | NCT07055386 A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM) | active not recruiting | 90 |
| 2026-06-16 | P3 | Eli Lilly and Company LLY | NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea | completed | 1152 |
| 2026-05-29 | P2 | Carmot Therapeutics, Inc. | NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus | Overweight or Obese; Type 2 Diabetes Mellitus (T2DM) | completed | 447 |
| 2026-05-29 | P3 | Shandong Suncadia Medicine Co., Ltd. | NCT06589765 A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin | Type 2 Diabetes | completed | 810 |
| 2026-05-27 | P2 | NodThera Ltd. (a Rezera company) | NCT07055516 Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus | Obesity and Type 2 Diabetes | completed | 176 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "type 2 diabetes"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.